Le Centre de recherche Douglas

OBJECTIVE: To investigate the association between newly developed type 2 diabetes (T2D) and incident psychopharmacological treatment and psychiatric hospital contact.METHODS: Via Danish registers, we identified all 56,640 individuals from the Central- and Northern Denmark Regions with newly developed T2D (defined by the first HbA1c measurement ≥6.5%) in 2000-2016 as well as 315,694 age and sex matched controls (without T2D). Those having received psychopharmacological treatment or having had a psychiatric hospital contact in the five years prior to the onset of T2D were not included. For this cohort, we first assessed the two-year incidence of psychopharmacological treatment and psychiatric hospital contact. Secondly, via Cox regression, we compared the incidence of psychopharmacological treatment/psychiatric hospital contact among individuals with T2D to propensity score matched controls - taking a wide range of potential confounders into account. Finally, via Cox proportional hazards regression, we assessed which baseline (T2D onset) characteristics were associated with subsequent psychopharmacological treatment and psychiatric hospital contact.RESULTS: A total of 8.3% of the individuals with T2D initiated psychopharmacological treatment compared to 4.6% of the age and sex matched controls. Individuals with T2D were at increased risk of initiating psychopharmacological treatment compared to the propensity score matched controls (HR=1.51, 95% CI=1.43-1.59), whereas their risk of psychiatric hospital contact was not increased to the same extent (HR=1.14, 95% CI=0.98-1.32). Older age, somatic comorbidity, and being divorced/widowed was associated with both psychopharmacological treatment and psychiatric hospital contact following T2D.CONCLUSION: Individuals with T2D are at elevated risk of requiring psychopharmacological treatment.